Moderna: Omicron Booster Candidate Shows Higher Neutralizing Antibody Response Against Subvariants
July 11 2022 - 09:02AM
Dow Jones News
By Michael Dabaie
Moderna Inc. said new clinical data on its bivalent Omicron, or
BA.1, booster candidate demonstrates significantly higher
neutralizing antibody response against Omicron subvariants BA.4/5
compared to the currently authorized booster.
The company said mRNA-1273.214 has now demonstrated
significantly higher antibody titers against all tested variants,
including Omicron BA.1 and BA.4/5 subvariants, ancestral virus,
Alpha, Beta, Delta, and Gamma.
One month after administration in previously vaccinated and
boosted participants, a 50 microgram booster dose of mRNA-1273.214
elicited significantly higher neutralizing antibody responses
against the Omicron subvariants BA.4 and BA.5 compared to the
currently authorized booster.
The new data follows results from June from its ongoing Phase
2/3 study.
Previous results showed a 50 microgram booster dose of
mRNA-1273.214 met all pre-specified primary objectives and was
generally well tolerated, the company said.
Moderna said it has completed regulatory submissions for
mRNA-1273.214 in the European Union, United Kingdom, and Australia,
and expects to complete most remaining filings this week
The company said it is simultaneously developing mRNA-1273.222,
a bivalent candidate based on BA.4/5, consistent with recent FDA
guidance.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
July 11, 2022 08:47 ET (12:47 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Mar 2023 to Mar 2024